Citi sets a CHF 185.00 target for Galderma stock

Published on 10/16/2026 at 15:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half sales rose 24.60 percent in 2026. Galderma stock costs EUR 187.85 on October 16, 2026 at 5:03 p.m. CEST.

Target and market position

Citi analyst Cedric Besnard set a CHF 185.00 price target on October 16, 2026.
Quarterly revenue reached CHF 3.07 billion and net profit CHF 434.28 million for the period ending June 30, 2026.
Galderma stock costs EUR 187.85 at Lang & Schwarz on October 16, 2026 at 5:03 p.m. CEST.
The next sales and revenue release is scheduled for October 21, 2026.

Galderma, CH1335392721, Illustration mit AI erstellt.

Galderma stock has a fresh CHF 185.00 price target from Citi analyst Cedric Besnard, who initiated coverage with a Buy rating on October 16, 2026. Against the SIX quote of CHF 174.15 at 2:50 p.m. CEST, the target stands 6.23 percent above the price. Galderma stock was trading at EUR 187.85 at Lang & Schwarz on October 16, 2026 at 5:03 p.m. CEST.

What does Citi's target imply?

The target is only one part of a wider analyst picture. TipRanks reported that Barclays maintained a Buy rating with a CHF 220.00 target in a report released on September 30, 2026. The same source says Galderma reported quarterly revenue of CHF 3.07 billion and net profit of CHF 434.28 million for the period ending June 30, 2026, compared with CHF 2.64 billion and CHF 209.31 million a year earlier.

Stock position and operating momentum

Galderma's SIX price was CHF 174.15 on October 16, 2026 at 2:50 p.m. CEST. The 52-week range was CHF 134.70 to CHF 188.25, putting the quote CHF 14.10 below the high and CHF 39.45 above the low. Trading volume stood at 160,313 shares against an average of 554,280 shares.

For the first half of 2026, net sales increased 24.60 percent at constant currency, according to MarketScreener. The company raised its full-year 2026 net sales growth guidance to 19.00 to 21.00 percent from 17.00 to 20.00 percent. S&P Global Ratings said the adjusted core EBITDA margin reached approximately 26.00 percent in its first-half 2026 assessment.

Valuation and upcoming date

Galderma had a market capitalization of CHF 40.6 billion, a P/E ratio of 57.92 and a dividend yield of 0.00 percent on October 16, 2026. The company is scheduled to publish its sales and revenue release for the third quarter of 2026 on October 21, 2026.

Comparison with peers

Galderma (SIX, CHF): P/E 57.92, market capitalization CHF 40.6 billion

Beiersdorf (Xetra, EUR): minus 0.71 percent, P/E 18.86, market capitalization EUR 17.6 billion

L'Oreal (Euronext Paris, EUR): minus 0.50 percent, P/E 34.36, market capitalization EUR 215.6 billion

Price perspective for investors

Galderma combines a high valuation multiple with strong reported sales growth and a target price below the latest analyst target from Barclays. The upcoming October 21, 2026 sales release is the next dated event for the stock.

The further course of trading is shown by the continuously updated real-time quote of Galderma stock.